<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7902231</journal-id>
<journal-id journal-id-type="pubmed-jr-id">32615</journal-id>
<journal-id journal-id-type="nlm-ta">Handb Exp Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Handb Exp Pharmacol</journal-id>
<journal-title-group>
<journal-title>Handbook of experimental pharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0171-2004</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28035530</article-id>
<article-id pub-id-type="pmc">5526216</article-id>
<article-id pub-id-type="doi">10.1007/164_2016_103</article-id>
<article-id pub-id-type="manuscript">NIHMS875783</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Serotonergic Mechanisms Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Terry</surname>
<given-names>Natalie</given-names>
</name>
<aff id="A1">Division of Pediatric Gastroenterology, Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA</aff>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Margolis</surname>
<given-names>Kara Gross</given-names>
</name>
<!--<email>kjg2133@cumc.columbia.edu</email>-->
<aff id="A2">Division of Pediatric Gastroenterology, Department of Pediatrics, Morgan Stanley Children’s Hospital, Columbia University Medical Center, New York, NY, USA</aff>
</contrib>
</contrib-group>
<pub-date pub-type="nihms-submitted">
<day>17</day>
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>25</day>
<month>7</month>
<year>2017</year>
</pub-date>
<volume>239</volume>
<fpage>319</fpage>
<lpage>342</lpage>
<!--elocation-id from pubmed: 10.1007/164_2016_103-->
<abstract>
<p id="P1">Serotonin (5-hydroxytryptamine; 5-HT) is best known as a neurotransmitter critical for central nervous system (CNS) development and function. 95% of the body’s serotonin, however, is produced in the intestine where it has been increasingly recognized for its hormonal, autocrine, paracrine, and endocrine actions. This chapter provides the most current knowledge of the critical autocrine and paracrine roles of 5-HT in intestinal motility and inflammation as well as its function as a hormone in osteocyte homeostasis. Therapeutic applications in each of these areas are also discussed.</p>
</abstract>
<kwd-group>
<kwd>Bone</kwd>
<kwd>Enteric nervous system</kwd>
<kwd>Intestinal inflammation</kwd>
<kwd>Intestine</kwd>
<kwd>Motility</kwd>
<kwd>Serotonin</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>